Immunological Monitoring of VZV Vaccination in Patients with Renal Failure versus Healthy Individuals.
Recruiting
- Conditions
- renal insufficiency herpes zoster vaccination prevention renal transplantation
- Registration Number
- NL-OMON25608
- Lead Sponsor
- Erasmus MC Rotterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1. Age ≥ 50 years;
2. Patients on waitlist for living-related kidney transplantation and their donors;
Exclusion Criteria
1. Use of immunosuppression (inhalation of corticosteroids is allowed);
2. Neomycine allergy;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. VZV-specific IgG and IgM levels;<br /><br>2. Percentage of VZV-reactive memory CD4+ and CD8+ T-cells.<br /><br /><br>CD3+ and CD14+ will be isolated from the peripheral blood cells to determine the percentage of VZV-specific CD4+ and CD8+ T-cells by flowcytometry [14] at the Transplantation Laboratory (7 tubes of 6 ml heparinized blood).<br /><br>Four samples of blood will be sampled from a vein in the forearm by venapunction by our nurses at day of inclusion (day 0), 1, 3 and 12 months after vaccination. At day 0 and 3 months VZV-specific titres and T-cell reactivity will be performed (8 tubes each time: 48 ml), and 1 and 12 months after vaccination VZV-specific titres and VZV-PCR will be performed (2 tubes: 12 ml).
- Secondary Outcome Measures
Name Time Method